Cervical-level injuries account for the majority of presented spinal cord injuries (SCIs), yet there are few therapies that successfully improve the overall quality of life for patients. Regenerative therapies aimed at ameliorating deficits in respiratory and motor function are urgently needed. Cellular transplantation strategies are a promising therapeutic avenue. These strategies seek to overcome the inhibitory environment of the injury site, increase native regenerative capacities, provide scaffolding to bridge the lesion, or replace injury-lost neurons and glia.Numerous considerations must be taken into account, however, when designing effective cellular transplantation therapies, most notably of which is cell source. Each cell source offers its own unique attributes-both positive and negative-that directly correspond with functional outcomes and clinical translation. Here we discuss three different cell types currently used in cellular transplantation strategies to treat cervical SCIs: mesenchymal stem cells (MSCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs). By illustrating the characteristics of each cell type and outlining the studies and clinical trials in which they have been featured, we hope to provide the reader with a detailed understanding of both their capabilities and also their potential drawbacks in experimental and clinical settings.